. Protein kinases are a large family of ubiquitous signaling enzymes in human cells. Their dysregulation often underlies diseases such as cancer, making them excellent therapeutic targets, when drug specificity can be achieved. However, the high structural and sequence conservation of the protein kinase catalytic domains has complicated the development of specific inhibitors. The few clinically-successful kinase inhibitors achieve specificity in part by binding only to distinct kinase conformations. While the analysis of thousands of X-ray crystal structures of protein kinases has shown that a single kinase domain can access different active and inactive conformations, little is known about how kinases interconvert between the conformations. The rationale of this proposal is that a quantitative understanding of the stability of these conformations and the dynamics of their interconversion are key to understanding kinase activity, regulation and ligand binding in health and disease states. The objective of this project is to describe the kinetic and equilibrium parameters for the conformational interconversions within the kinase domains of tyrosine kinases Src, Abl, Brk and the promiscuous drug-binding tyrosine kinase DDR1. This proposal is part of a continuum of research centered around four questions that concern the role of conformational dynamics of protein kinases in kinase regulation (Q1), allosteric modulation (Q2), ligand binding kinetics (Q3) and drug specificity/kinase promiscuity (Q4): Q1: What are the thermodynamics and kinetics of conformational exchange in tyrosine kinases? Q2: How are allosteric signals communicated through protein domains and how can binding sites for allosteric regulators be predicted? Q3: What are the molecular determinants of ligand-binding kinetics? Q4: Why do some kinases bind inhibitors promiscuously and how can specific inhibitors with cellular potency be developed? The PI and his team will study these questions through a combination of structural methods (X-ray and NMR), ligand binding kinetics, protein engineering, chemical biology and computational methods. A network of productive collaborations supports this project. The impact of this project is to provide clinicians with the mechanism of resistance mutations, cell biologists with parameters to understand kinase signaling and medicinal chemists with parameters to modulate ligand binding kinetics. The long-term goal is to lay the foundation for the design of safe and effective, sufficiently specific, inhibitors of disease-associated protein kinases.

Public Health Relevance

This project is relevant to public health because the understanding of how conformational dynamics affect the regulation, allosteric modulation, ligand binding kinetics and drug specificity of protein kinases is expected to increase understanding of disease-relevant kinase signaling pathways. The project aims to advance this fundamental knowledge and to develop macrocyclic therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Unknown (R35)
Project #
3R35GM119437-03S1
Application #
9697601
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Fabian, Miles
Project Start
2016-07-15
Project End
2021-05-31
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
State University New York Stony Brook
Department
Pharmacology
Type
Schools of Medicine
DUNS #
804878247
City
Stony Brook
State
NY
Country
United States
Zip Code
11794
Albanese, Steven K; Parton, Daniel L; I??k, Mehtap et al. (2018) An Open Library of Human Kinase Domain Constructs for Automated Bacterial Expression. Biochemistry 57:4675-4689
Tong, Michael; Pelton, Jeff G; Gill, Michelle L et al. (2017) Survey of solution dynamics in Src kinase reveals allosteric cross talk between the ligand binding and regulatory sites. Nat Commun 8:2160
Alford, Vincent M; Kamath, Anushree; Ren, Xiaodong et al. (2017) Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions. ACS Chem Biol 12:2788-2803
Philip, F; Ha, E E; Seeliger, M A et al. (2017) Measuring Phospholipase D Enzymatic Activity Through Biochemical and Imaging Methods. Methods Enzymol 583:309-325
Chu, Wen-Ting; Nesbitt, Natasha M; Gnatenko, Dmitri V et al. (2017) Enzymatic Activity and Thermodynamic Stability of Biliverdin IX? Reductase Are Maintained by an Active Site Serine. Chemistry 23:1891-1900
Kükenshöner, Tim; Schmit, Nadine Eliane; Bouda, Emilie et al. (2017) Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies. J Mol Biol 429:1364-1380
Huculeci, Radu; Cilia, Elisa; Lyczek, Agatha et al. (2016) Dynamically Coupled Residues within the SH2 Domain of FYN Are Key to Unlocking Its Activity. Structure 24:1947-1959
Lebedev, Ivan; Nemajerova, Alice; Foda, Zachariah H et al. (2016) A Novel In Vitro CypD-Mediated p53 Aggregation Assay Suggests a Model for Mitochondrial Permeability Transition by Chaperone Systems. J Mol Biol 428:4154-4167
Aleem, Saadat; Georghiou, George; Kleiner, Ralph E et al. (2016) Structural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic Macrocycles. Cell Chem Biol 23:1103-1112